The use of glucagon-like peptide 1 receptor agonist (GLP-1 RA) and dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 RA (GIP/GLP-1 RA) classes has increased substantially over the past several years for treating type 2 diabetes and obesity. Increased demand for these pharmacotherapies has resulted in temporary product shortages for both GLP-1 RA and dual GIP/GLP-1 RA medications. These shortages, in part, have led to entities producing and marketing compounded formulations that bypass regulatory measures, raising safety, quality, and efficacy concerns. Even as shortages resolve, compounded GLP-1 RA and GIP/GLP-1 RA products continue to be heavily marketed to people with diabetes and obesity. The purpose of this statement by the American Diabetes Association is to guide health care professionals and people with diabetes and/or obesity in these circumstances of medication unavailability to promote optimal care and medication use safety.

在过去几年中，用于治疗2型糖尿病和肥胖症的胰高血糖素样肽1受体激动剂（GLP-1 RA）以及葡萄糖依赖性促胰岛素多肽（GIP）和GLP-1 RA双联药物（GIP/GLP-1 RA）的使用大幅增加。对这些药物疗法需求的增加导致GLP-1 RA和GIP/GLP-1 RA双联药物出现暂时性产品短缺。这些短缺在一定程度上导致一些实体绕过监管措施生产和销售复方制剂，从而引发了对安全性、质量和疗效的担忧。即使短缺问题得到解决，GLP-1 RA和GIP/GLP-1 RA复方产品仍在糖尿病和肥胖症患者中大量销售。美国糖尿病协会发表本声明的目的是，在药物供应不足的情况下，为医护人员和糖尿病及/或肥胖症患者提供指导，以促进最佳护理和用药安全。